Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Entrepreneurs know what it’s like to dream big and take risk, so they naturally tend to support people who do the same. For that, I’m immensely thankful.
I was blown away, and humbled, by the words of encouragement I heard last week at the Timmerman Report launch party in my hometown of Seattle. There was a great mixed crowd of biotech entrepreneurs, executives, students, postdocs, journalism friends, and my family (including a certain scene-stealing toddler).
Special thanks go out to Alexandria Real Estate Equities for allowing me to use the Agora Conference Center for the party. Seattle-based photographer Robert Wade was on hand, and took all of the great candid photos you see in the gallery below. Matt and Carlin Pressnall unfortunately couldn’t make it, but I wanted to make sure to thank them for designing and developing a first-rate reading experience for biotech professionals who use laptops, tablets, or smartphones.
With that, here are some of the photo highlights. There will be many more at the East Coast launch party on Apr. 16 at Pfizer Cambridge. You can click on the thumbnail images for a larger view.
Timmerman Report is coming to Boston next month for, oh, two of the bigger events of my life.
Please mark your calendars for the first event—the Timmerman Report East Coast Launch Party. It will be 4-6 pm Thursday, Apr. 16 at Pfizer Cambridge, 610 Main Street, Cambridge, Mass.
This will be a free gathering to thank the first wave of subscribers to this new independent biotech journalism venture. I expect a high-powered crowd of biotech CEOs, scientists, investors, and entrepreneurs. There won’t be any official program, just some food and drink and fellowship. There will also be a door prize or two. Sources say some slick New Balance running shirts may be involved.
That brings me to the question of beer. Adult beverages and snacks will be available, but sadly, I will not partake. Water will be my drink of choice. That’s because the party is just 3.5 days before I’m set to run in the Boston Marathon for the first time. I’m not going to let some beer and snack cravings slow me down.
I have one request. Although the event is free, please RSVP here so we have an accurate headcount and you can sign in seamlessly at the front desk at Pfizer Cambridge. That’s it. See you there Apr. 16.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.
